IL2 and renal cell carcinoma: Considering the rationale for the efficacy of YM155 combined with IL-2, different independent modes of action of IL-2, which induce antitumor responses, and the action of YM155, which causes apoptosis, may act synergistically to kill RCC cells in vivo.